NewAmsterdam Pharma Appoints Juliette Audet as CBO

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) has recently appointed Juliette Audet as the Chief Business Officer (CBO), effective April 1, 2024. Ms. Audet brings over a decade of experience in senior leadership roles in the biopharmaceutical industry and has been a trusted advisor to NewAmsterdam as an investor and member of the board of directors since 2020.

NewAmsterdam is currently focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C) for whom existing therapies are not sufficiently effective or well-tolerated. The company is particularly interested in obicetrapib, an oral, low-dose, and once-daily CETP inhibitor, either alone or as a fixed-dose combination with ezetimibe, as preferred LDL-C lowering therapies. These therapies are intended to be used as an adjunct to statin therapy for high-risk CVD patients with elevated LDL-C.

Ms. Audet's appointment comes at a crucial time for NewAmsterdam as the company expects two pivotal readouts for obicetrapib this year. This indicates significant progress in the company's efforts to bring this potential therapy to millions of underserved patients globally.

Furthermore, NewAmsterdam is working on building a commercial organization to effectively bring the CETP inhibitor to the market if approved. Ms. Audet's extensive pharmaceutical business development, finance, and operational expertise, along with her experience as a partner at Forbion, positions her well to contribute to NewAmsterdam's mission of transforming the standard of care for high-risk CVD patients.

Ms. Audet has an impressive educational background, with an MBA with distinction from Harvard Business School and an M.Sc. in Physics from the Swiss Federal Institute of Technology.

Today the company's shares have moved -1.0% to a price of $23.42. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.